Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort

American Journal of Infection Control

Volumn 47, Issue 1, 2019, Pages 2-8

  Carvour, Martha L ^a   Wilder, Shane L ^a   Ryan, Keenan L ^b   Walraven, Carla ^b   Qeadan, Fares ^a   Brett, Meghan ^a   Page, Kimberly ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

Clostridium difficile; Health care associated infection; Hospital epidemiology; Probiotics

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFPROZIL; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DICLOXACILLIN; ERTAPENEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EXPOSURE; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW MEXICO; PREDICTIVE VALUE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SOCIAL STATUS; TREATMENT DURATION; ADOLESCENT; AGED; CLOSTRIDIUM INFECTION; CROSS INFECTION; ENVIRONMENTAL EXPOSURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLINICAL DECISION RULES; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROBIOTICS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 85053011129     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2018.07.014     Document Type: Article

References (32)

1. CLSI. Clinical and Laboratory Standards Institute supplement M100, 28th edition. Available from: http://em100.edaptivedocs.net/Login.aspx. Accessed July 16, 2018.
2. Magill, SS, Edwards, JR, Bamberg, W, Beldavs, ZG, Dumyati, G, Kainer, MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
3. Lessa, FC, Mu, Y, Bamberg, WM, Beldavs, ZG, Dumyati, GK, Dunn, JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
4. Dubberke, ER, Olsen, MA., Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55:Suppl 2 (2012), 88–92.
5. Shrestha, MP, Bime, C, Taleban, S., Decreasing Clostridium difficile-associated fatality rates among hospitalized patients in the United States: 2004-2014. Am J Med 131 (2018), 90–96.
6. Eyre, DW, Walker, AS, Wyllie, D, Dingle, KE, Griffiths, D, Finney, J, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 55:Suppl 2 (2012), 77–87.
7. Galpérine, T, Guery, B., Exploring ways to improve CDI outcomes. Médecine Mal Infect 48 (2018), 10–17.
8. Allen, SJ., The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin North Am 29 (2015), 135–144.
9. Hell, M, Bernhofer, C, Stalzer, P, Kern, JM, Claassen, E., Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Benef Microbes 4 (2013), 39–51.
10. Goldenberg, JZ, Ma, SS, Saxton, JD, Martzen, MR, Vandvik, PO, Thorlund, K, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev(5), 2013, CD006095.
11. Evans, CT, Johnson, S., Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis 60:Suppl 2 (2015), 122–128.
12. Pattani, R, Palda, VA, Hwang, SW, Shah, PS., Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 7 (2013), e56–e67.
13. Medicare.gov. Hospital Compare. Available from: https://www.medicare.gov/hospitalcompare/search.html?. Accessed July 16, 2018.
14. Slimings, C, Riley, TV, Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 881–891.
15. Crew, PE, Rhodes, NJ, O'Donnell, JN, Miglis, C, Gilbert, EM, Zembower, TR, et al. Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection. Am J Infect Control 46 (2018), 270–275.
16. van Werkhoven, CH, van der Tempel, J, Jajou, R, Thijsen, SF, Diepersloot, RJ, Bonten, MJ, et al. Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clin Microbiol Infect, 21, 2015 786.e1-8.
17. Brown, KA, Daneman, N, Arora, P, Moineddin, R, Fisman, DN., The co-seasonality of pneumonia and influenza with Clostridium difficile infection in the United States, 1993-2008. Am J Epidemiol 178 (2013), 118–125.
18. Motzkus-Feagans, CA, Pakyz, A, Polk, R, Gambassi, G, Lapane, KL., Statin use and the risk of Clostridium difficile in academic medical centres. Gut 61 (2012), 1538–1542.
19. Nseir, W, Bishara, J, Mograbi, J, Mahamid, M, Khalaila, W, Taha, M, et al. Do statins protect against the development of Clostridium difficile-associated diarrhoea?. J Antimicrob Chemother 68 (2013), 1889–1893.
20. Kwok, CS, Arthur, AK, Anibueze, CI, Singh, S, Cavallazzi, R, Loke, YK., Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107 (2012), 1011–1019.
21. Piper, MS, Saad, RJ, Diabetes mellitus and the colon. Curr Treat Options Gastroenterol 15 (2017), 460–474.
22. Brown, KA, Khanafer, N, Daneman, N, Fisman, DN, Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57 (2013), 2326–2332.
23. Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR., A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996), 1373–1379.
24. University of New Mexico Health Sciences Center. 2017 NM health data summary. Available from: https://hsc.unm.edu/research/ctsc/assets/doc/CERC/nm-health-data-summary.pdf. Accessed July 16, 2018.
25. Goldstein, EJC, Citron, DM, Claros, MC, Tyrrell, KL., Bacterial counts from five over-the-counter probiotics: are you getting what you paid for?. Anaerobe 25 (2014), 1–4.
26. Maziade, P-J, Andriessen, JA, Pereira, P, Currie, B, Goldstein, EJC., Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 29 (2013), 1341–1347.
27. Chopra, T, Goldstein, EJC., Clostridium difficile infection in long-term care facilities: a call to action for antimicrobial stewardship. Clin Infect Dis 60:Suppl 2 (2015), 72–76.
28. Mao, EJ, Kelly, CR, Machan, JT., Racial differences in Clostridium difficile infection rates are attributable to disparities in health care access. Antimicrob Agents Chemother 59 (2015), 6283–6287.
29. Mello, CS, Carmo-Rodrigues, MS, Filho, HBA, Melli, LC, Tahan, S, Pignatari, AC, et al. Gut microbiota differences in children from distinct socioeconomic levels living in the same urban area in Brazil. J Pediatr Gastroenterol Nutr 63 (2016), 460–465.
30. Ravel, J, Gajer, P, Abdo, Z, Schneider, GM, Koenig, SS, McCulle, SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108:Suppl 1 (2011), 4680–4687.
31. Rose, G., Sick individuals and sick populations. Int J Epidemiol 14 (1985), 32–38.
32. Schwartz, S, Carpenter, KM., The right answer for the wrong question: consequences of type III error for public health research. Am J Public Health 89 (1999), 1175–1180.